Drisdol Related Published Studies
Well-designed clinical trials related to Drisdol (Ergocalciferol)
Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial. [2011.08.30]
Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. [2011.04]
Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000
IU monthly in older adults. [2011]
Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. [2009.06]
Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. [2008.01.14]
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. [2007.03.20]
Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. [2005.08.08]
Well-designed clinical trials possibly related to Drisdol (Ergocalciferol)
Effect of paricalcitol on circulating parathyroid hormone in X-linked
hypophosphatemia: a randomized, double-blind, placebo-controlled study. [2014]
Health characteristics and outcomes of two randomized vitamin D supplementation
trials during pregnancy: a combined analysis. [2013]
A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation. [2011.06.20]
The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. [2011.04]
Efficient tetanus toxoid immunization on vitamin D supplementation. [2011.03]
Vitamin D(3) is more potent than vitamin D(2) in humans. [2011.03]
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. [2011.01]
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. [2011]
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a
phase II, double-blind, placebo-controlled, randomized trial. [2011]
A randomized controlled trial of vitamin D dosing strategies after acute hip
fracture: no advantage of loading doses over daily supplementation. [2011]
Vitamin D: emerging roles in infection and immunity. [2010.12]
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. [2010.11.06]
Effect of paricalcitol on the urinary peptidome of kidney transplant patients. [2010.10]
A randomized, controlled trial of vitamin D supplementation upon musculoskeletal health in postmenarchal females. [2010.10]
A Randomized, Controlled Trial of Vitamin D Supplementation upon Musculoskeletal Health in Postmenarchal Females. [2010.07.14]
Pilot study to evaluate the effect of short-term improvement in vitamin D status on glucose tolerance in patients with type 2 diabetes mellitus. [2010.07]
Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults. [2010.06]
Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial. [2010.05]
A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. [2010.02]
Milk fortified with the current adequate intake for vitamin D (5 microg) increases serum 25-hydroxyvitamin D compared to control milk but is not sufficient to prevent a seasonal decline in young women. [2010]
Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. [2010]
Vitamin D supplementation and bone mass accrual in underprivileged adolescent Indian girls. [2010]
Vitamin D: emerging roles in infection and immunity. [2010]
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. [2009.10]
Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. [2009.09.24]
The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets. [2009.09]
Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study. [2009.08]
Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. [2009.08]
Meals and dephytinization affect calcium and zinc absorption in Nigerian children with rickets. [2009.05]
Effect of free vitamin D(2) drops on serum 25-hydroxyvitamin D in infants with immigrant origin: a cluster randomized controlled trial. [2009.04]
Vitamin D status modification by two slightly hypocaloric diets in young overweight/obese women. [2009.03]
Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients. [2009.01]
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? [2009]
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. [2009]
Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. [2008.08]
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. [2008.08]
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. [2008.04.15]
Calcium balance during calcitriol and paricalcitol administration in healthy humans. [2008.03]
Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. [2008.03]
Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. [2008.03]
Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D. [2008.02]
Effect of free vitamin D(2) drops on serum 25-hydroxyvitamin D in infants with immigrant origin: a cluster randomized controlled trial. [2008.01.30]
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. [2008]
Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. [2007.12]
Response to teriparatide in patients with baseline 25-hydroxyvitamin d insufficiency or sufficiency. [2007.12]
Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. [2007.09.10]
Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women. [2007.06]
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. [2007.06]
Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. [2007.03]
Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. [2006.09]
Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. [2006.07]
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. [2006.07]
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women. [2006.05]
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. [2006.02.21]
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. [2006.02]
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. [2006]
Antiproteinuric effect of oral paricalcitol in chronic kidney disease. [2005.12]
Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. [2005.11]
Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. [2005.11]
Relationships among vitamin D levels, parathyroid hormone, and calcium absorption in young adolescents. [2005.10]
Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial. [2005.08]
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. [2005.08]
Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly. [2005.07]
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. [2005.05.11]
Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. [2005]
Other research related to Drisdol (Ergocalciferol)
Comparative efficacy and safety of different doses of ergocalciferol
supplementation in patients with metabolic syndrome. [2014]
Calculated free and bioavailable vitamin D metabolite concentrations in vitamin
D-deficient hip fracture patients after supplementation with cholecalciferol and
ergocalciferol. [2013]
Ergocalciferol decreases erythropoietin resistance in children with chronic
kidney disease stage 5. [2013]
Ergocalciferol treatment and aspects of mineral homeostasis in patients with
chronic kidney disease stage 4-5. [2013]
Ergocalciferol supplementation in children with CKD delays the onset of secondary
hyperparathyroidism: a randomized trial. [2012]
Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency. [2010.08]
Failure of alphacalcidol (1alpha-hydroxyvitamin D3) in treating nutritional rickets and the biochemical response to ergocalciferol. [2010.07]
Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate? [2010.04]
Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. [2009.11]
The lack of vitamin D toxicity with megadose of daily ergocalciferol (D2) therapy: a case report and literature review. [2009.07]
Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis. [2009.07]
Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. [2009.06]
Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin d2) or cholecalciferol (vitamin d3) in the elderly. [2008.08]
Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. [2008.07]
Short and Long Term Variations in Serum Calciotrophic Hormones after a Single Very Large Dose of Ergocalciferol (Vitamin D2) or Cholecalciferol (Vitamin D3) in the Elderly. [2008.05.20]
Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. [2007.07]
Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. [2007]
Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. [2007]
Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. [2006.12]
The case against ergocalciferol (vitamin D2) as a vitamin supplement. [2006.10]
Severe hypercalcemia after transition from calcium carbonate to calcium citrate in an elderly woman treated with ergocalciferol 50,000 IU per day. [2006.03]
Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. [2005.07.15]
Other possibly related research studies
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. [2006]
[Immobilization and hip fracture] [2006.12]
Doxercalciferol treatment of secondary hyperparathyroidism. [2006.11]
Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both? [2006.07]
Mortality risk among hemodialysis patients receiving different vitamin D analogs. [2006.11]
[Breast density: a biomarker to better understand and prevent breast cancer] [2006.09.01]
Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. [2006.09.04]
|
